# Bank of America

Type: Company (BAC)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/bank-of-america-company
Canonical HTML page: https://getbiobrief.com/entity/bank-of-america-company

## Timeline

- **2026-03-12**: BofA Price Target Hike — Bank of America increases price target, highlighting R&D productivity and MedTech growth.
- **2026-03-07**: Fast-Track Approval — USFDA grants approval for Tecvayli-Darzalex combination via fast-track voucher program.
- **2026-03-05**: 12-Month High — JNJ shares reach a new yearly peak following FDA approval for multiple myeloma combo.

## Recent coverage (3 stories)

### Biotech Sell-Off: Novavax Downgraded to Sell Despite Revenue Beat
2026-08-04 12:11:16 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market.
Full story: https://getbiobrief.com/story/novavax-sell-downgrade-biotech-pharma

### REGENXBIO CMO Sells $688K Shares After Q1 Miss, Yet Analysts See 99% Upside
2026-07-06 01:38:05 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

REGENXBIO Chief Medical Officer Steve Pakola offloaded 56,333 shares for $688,756 following a disastrous Q1 miss, but analysts maintain price targets implying up to 99% upside. The insider sales add tension to a gene therapy story already defined by high risk and potential reward.
Full story: https://getbiobrief.com/story/regenxbio-cmo-sells-688k-after-q1-miss-analyst-upside

### BofA Bullish on Johnson & Johnson as Pipeline Momentum Accelerates
2026-03-12 08:11:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets.
Full story: https://getbiobrief.com/story/bofa-jnj-price-target-pipeline-growth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.